-
Highlights of the Safety committee: November 2022
Highlights of the Safety committee: November 2022
-
Highlights of the Safety committee: November 2022
Highlights of the Safety committee: November 2022
PRAC finalised the review of heavy menstrual bleeding with COVID-19 mRNA vaccines, confirmed the withdrawal of amfepramone obesity medicines, and recommended measures for JAK inhibitors
-
Use of mRNA COVID-19 vaccines in young children
Use of mRNA COVID-19 vaccines in young children
-
Use of mRNA COVID-19 vaccines in young children
Use of mRNA COVID-19 vaccines in young children
EMA recommended authorising the use of Comirnaty in children aged 6 months to 4 years, and Spikevax for those aged 6 months to 5 years
-
New adapted COVID-19 vaccine
New adapted COVID-19 vaccine
-
New adapted COVID-19 vaccine
New adapted COVID-19 vaccine
This adapted version of Spikevax targets the Omicron subvariants BA.4 and BA.5. It is meant for use in vaccinated people aged 12 and over
-
EMA's response to monkeypox
EMA's response to monkeypox
-
EMA's response to monkeypox
EMA's response to monkeypox
Find out about monkeypox disease, medicines available in the EU to tackle it and how EMA and its EU partners are helping to combat the outbreak
Information for you
Key content
Services & databases
-
List item
Clinical Trials website
-
List item
Account Management portal
-
List item
eSubmission
-
List item
EudraVigilance (human)
-
List item
EudraVigilance Veterinary
-
List item
Veterinary Medicines information website
-
List item
Suspected adverse drug reactions database
-
List item
Clinical data
-
List item
SPOR data management services
-
List item
Service Desk
-
List item
IRIS platform
-
List item
Public register of parallel distribution notices
-
List item
European Vaccination Information Portal